D-0687-2022 Class II Terminated

Recalled by Teligent Pharma, Inc. — Buena, NJ

FDA drug recall D-0687-2022 was initiated by Teligent Pharma, Inc. on Mar 15, 2022 and is designated Class II. Reason for recall: cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program. The recall status is terminated (terminated Jun 17, 2024). Affected quantity: 43,956 tubes.

Recall Details

Product Type
Drugs
Report Date
Mar 30, 2022
Initiation Date
Mar 15, 2022
Termination Date
Jun 17, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
43,956 tubes

Product Description

Gentamicin Sulfate Ointment USP 0.1%, packaged as a) 15 grams tube, NDC 52565-090-15; b) 30 grams tube, NDC 52565-090-30, Rx Only, Manufactured by: Teligent Pharma, Inc., Buena, NJ 08310.

Reason for Recall

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Distribution Pattern

Nationwide in the USA and Puerto Rico

Code Information

Batch: a) 16878, 16912, Exp. 5/31/2023; b)16878, Exp. 5/21/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0687-2022
openFDA file date
Nov 3, 2026
Loaded by RegDataLab
Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0687-2022. Report a data issue: hello@regdatalab.com.